Accueil   Diary - News   All news VALBIOTIS to present novel data about TOTUM-63 and metabolic diseases prevention

VALBIOTIS to present novel data about TOTUM-63 and metabolic diseases prevention

VALBIOTIS to present novel data about TOTUM-63 and metabolic diseases prevention at the 2019 scientific sessions
of the American Diabetes Association

 

  • TOTUM-63 reduces inflammation in visceral adipose tissue, one of the mechanisms leading to type 2 diabetes and metabolic diseases.
  • The efficacy of TOTUM-63 on sugar and lipid metabolism is confirmed in a murine model of prediabetes.
  • These results were obtained by an independent study led by Dr. Bruno GUIGAS at Leiden University (Netherlands).

 

La Rochelle, 7 June 2019 (7:35 CEST) – VALBIOTIS FR0013254851 – ALVAL / PEA/SME eligible), a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, today announced that new preclinical results of TOTUM-63 obtained independently by Leiden University (Netherlands) will be presented at the 2019 scientific sessions of the American Diabetes Association, being held from June 7 to 11 in San Francisco, California. In a murine model of prediabetes, TOTUM-63 reduced inflammation in visceral adipose tissue, one of the pathophysiological mechanisms of metabolic diseases, especially type 2 diabetes. Moreover, this study also confirmed the efficacy of TOTUM-63 on sugar and lipid metabolism in this preclinical model.

Read the press release

By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Service. More information... Close